<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
 <result pre="combinations that are highly effective in blocking Herpes simplex virus" exact="type 1" post="(HSV-1) infection. We discovered two antiviral drug combinations act"/>
 <result pre="drug against one particular target or outcome, such as stopping" exact="infection" post="or limiting disease pathology. However, potential side effects and"/>
 <result pre="particular target or outcome, such as stopping infection or limiting" exact="disease" post="pathology. However, potential side effects and off-label indications are"/>
 <result pre="best drug or combination of drugs to optimally treat a" exact="disease" post="without using conventional drug screening approaches are needed for"/>
 <result pre="et al., 2012; Schweizer and Zhang, 2013). Treatment of different" exact="disease" post="states through combinations of multiple drugs is used to"/>
 <result pre="resistance, and sustain high efficacy with low toxicity often with" exact="lower" post="doses of the individual drug components. The use of"/>
 <result pre="The use of drug combinations is well documented in both" exact="cancer" post="and infectious disease therapy (Al-Lazikani et al., 2012; Arts"/>
 <result pre="of drug combinations is well documented in both cancer and" exact="infectious disease" post="therapy (Al-Lazikani et al., 2012; Arts and Hazuda, 2012;"/>
 <result pre="drug combinations is well documented in both cancer and infectious" exact="disease" post="therapy (Al-Lazikani et al., 2012; Arts and Hazuda, 2012;"/>
 <result pre="determined due to their ability to inhibit Herpes simplex virus" exact="type 1" post="(HSV-1) infection. These combinations were identified through a Feedback"/>
 <result pre="to us by phosphoflow analysis of a drug combination or" exact="disease" post="state may allow us to better design specific therapeutics"/>
 <result pre="development is often focused on the singular outcome of limiting" exact="viral infection." post="However, side effects and potential off-label or secondary indications"/>
 <result pre="limiting viral infection. However, side effects and potential off-label or" exact="secondary" post="indications for the use of a drug are often"/>
 <result pre="ribavirin (RIB) or interferons (IFNs)) could both effectively inhibit HSV-1" exact="infection" post="(Ding et al., 2012). Though both drug combinations were"/>
 <result pre="our findings into the signaling changes involved in the HSV-1" exact="infection" post="to directly target those changes with antiviral therapies. 2"/>
 <result pre="therapies. 2 Materials and methods 2.1 Cell culture and HSV-1" exact="infections" post="This in vitro investigation was carried out in NIH"/>
 <result pre="2012). Viruses were diluted in DMEM to a multiplicity of" exact="infection" post="(MOI) of 0.1. 2.2 Drugs and solutions IFN-α, IFN-β,"/>
 <result pre="in staining medium. Antibodies are against Akt (also known as" exact="Protein" post="kinase B), ERK (extracellular signal-related kinase), JNK (c-Jun N-terminal"/>
 <result pre="error. 2.5 Assessing pS6 kinase inhibitor on in vitro HSV-1" exact="infection" post="To validate the cause-effect relationships between pS6 signaling and"/>
 <result pre="pSTAT1, and pSTAT3 using phosphoflow. 2.6 Animal model of HSV-1" exact="infection" post="In vivo compound treatment and stimulations were performed on"/>
 <result pre="infection In vivo compound treatment and stimulations were performed on" exact="female" post="KOS strain mice. All animal handling was performed in"/>
 <result pre="25 μL PBS vehicle via vaginal administration on day 0. HSV-1" exact="infection" post="was allowed to occur for 24 h post virus administration."/>
 <result pre="administration. The first vaginal lavage was collected at 24 h post" exact="infection" post="(day 1) followed immediately by a 50 μL drug treatment"/>
 <result pre="at 72 h post-infection (24 h post-second-round drug treatment) (day 3). HSV-1" exact="viral" post="copy number in vaginal lavage was quantified by plaque"/>
 <result pre="data points. Statistical differences were determined using a t-Test between" exact="viral" post="levels at day 2 or day 3, SL0101 or"/>
 <result pre="and pSTAT6), here we show only pS6 and pSTAT1. The" exact="complete" post="panel is shown in Supplementary Fig. 1. B. Comparison"/>
 <result pre="from three independent experiments. 3.3 Monitoring cellular signaling and HSV-1" exact="infection" post="after post-infection treatment To better understand how these drugs"/>
 <result pre="we next systemically evaluated changes in the phosphoprotein panel during" exact="viral" post="infections treated with drug combinations. Compared to uninfected cells"/>
 <result pre="next systemically evaluated changes in the phosphoprotein panel during viral" exact="infections" post="treated with drug combinations. Compared to uninfected cells treated"/>
 <result pre="treatments, as drug treatments would almost always take place after" exact="infection" post="is detected (Fig. 3 A). We used HSV-1 that"/>
 <result pre="allowed us to distinguish changes in cellular signaling induced by" exact="infection" post="on the single cell level. Fig. 3 Cellular Signaling"/>
 <result pre="the single cell level. Fig. 3 Cellular Signaling During Drug-Treated" exact="Viral Infection." post="A. Host cells were infected with HSV-1, and 8 h"/>
 <result pre="0.5 h after drug treatments, all infected samples had approximately equivalent" exact="viral infection" post="levels/percentages, which indicates that the drugs would not instantly"/>
 <result pre="after drug treatments, all infected samples had approximately equivalent viral" exact="infection" post="levels/percentages, which indicates that the drugs would not instantly"/>
 <result pre="which indicates that the drugs would not instantly lead to" exact="viral" post="reduction. C. 16 h post-treatment (24 h post-infection), pAKT, pMAPKAPK2,"/>
 <result pre="pS6 and pSTAT1 were found to be involved during the" exact="viral infection" post="and inhibition process. As a reminder: high dose IFNs"/>
 <result pre="and pSTAT1 were found to be involved during the viral" exact="infection" post="and inhibition process. As a reminder: high dose IFNs"/>
 <result pre="infected with HSV-1 were done so at a multiplicity of" exact="infection" post="(MOI) of 0.1 (+HSV) for 8 h after which"/>
 <result pre="in +HSV samples was low across all treatments, indicating that" exact="viral infection" post="was still in progress and that the majority of"/>
 <result pre="+HSV samples was low across all treatments, indicating that viral" exact="infection" post="was still in progress and that the majority of"/>
 <result pre="remained uninfected. Neither IFN-rich nor RIB-rich treatments lowered levels of" exact="viral infection" post="in an instantaneous manner (Fig. 3C). 16 h after"/>
 <result pre="uninfected. Neither IFN-rich nor RIB-rich treatments lowered levels of viral" exact="infection" post="in an instantaneous manner (Fig. 3C). 16 h after"/>
 <result pre="samples increased extensively throughout the cell population indicating that the" exact="viral infection" post="was able to infect the whole cell population during"/>
 <result pre="increased extensively throughout the cell population indicating that the viral" exact="infection" post="was able to infect the whole cell population during"/>
 <result pre="cell population during this time frame. In this model with" exact="virus infection" post="prior to drug treatment, drug combination Optimal_B (RIB-rich combination)"/>
 <result pre="population during this time frame. In this model with virus" exact="infection" post="prior to drug treatment, drug combination Optimal_B (RIB-rich combination)"/>
 <result pre="drug combination Optimal_B (RIB-rich combination) outperformed Optimal_A (IFN-rich combination) in" exact="viral" post="inhibition at 16 h post treatment. Although Optimal_A and"/>
 <result pre="(Ding et al., 2012), drug combination Optimal_A barely reduced the" exact="viral infection" post="level in cells infected with virus prior to treatment"/>
 <result pre="et al., 2012), drug combination Optimal_A barely reduced the viral" exact="infection" post="level in cells infected with virus prior to treatment"/>
 <result pre="This may be due to the previous work using a" exact="viral" post="co-infection/treatment model for determining the optimal drug combinations. 3.4"/>
 <result pre="3.4 Changes in distinct signaling nodes after post-infection treatment of" exact="viral infection" post="The results in Fig. 3 suggest that IFN does"/>
 <result pre="Changes in distinct signaling nodes after post-infection treatment of viral" exact="infection" post="The results in Fig. 3 suggest that IFN does"/>
 <result pre="directly eradicate virus in already infected cells; instead IFN inhibits" exact="viral infection" post="by targeting uninfected cells and preparing them to avoid"/>
 <result pre="eradicate virus in already infected cells; instead IFN inhibits viral" exact="infection" post="by targeting uninfected cells and preparing them to avoid"/>
 <result pre="by targeting uninfected cells and preparing them to avoid further" exact="viral" post="invasion, which is in line with the known biological"/>
 <result pre="in line with the known biological mechanisms of IFN. Once" exact="viral infection" post="had begun in the cell population, IFN could not"/>
 <result pre="line with the known biological mechanisms of IFN. Once viral" exact="infection" post="had begun in the cell population, IFN could not"/>
 <result pre="the cell population, IFN could not reduce the level of" exact="viral infection." post="In contrast, Optimal_B (RIB-rich combination) was effective in this"/>
 <result pre="drug treatment. These results indicate that RIB can directly target" exact="viral" post="replication inside the cells. Differences in phosphoprotein signaling became"/>
 <result pre="a decrease in pS6 levels and a reduction in HSV-1" exact="viral" post="burden (Fig. 4 A). pSTAT1 levels were diminished in"/>
 <result pre="pSTAT1 levels were recovered by IFN treatments (Fig. 4B). HSV-1" exact="infection" post="decreased pMAPKAPK2 levels, whereas blocking HSV-1 infection with ACV"/>
 <result pre="(Fig. 4B). HSV-1 infection decreased pMAPKAPK2 levels, whereas blocking HSV-1" exact="infection" post="with ACV containing treatments increased pMAPKAPK2 signaling (Fig. 4C)."/>
 <result pre="in the HSV-1 positive population (Fig. 4E). Overall, when HSV-1" exact="viral infection" post="was present, phosphoprotein changes became more complex. However, the"/>
 <result pre="the HSV-1 positive population (Fig. 4E). Overall, when HSV-1 viral" exact="infection" post="was present, phosphoprotein changes became more complex. However, the"/>
 <result pre="still pS6. The correlation between IFN, pSTAT1 status, and HSV-1" exact="infection" post="has been widely reported and part of the known"/>
 <result pre="pS6 levels, and HSV-1 infection. Fig. 4 Drug Treatment of" exact="Viral Infection" post="Affecting Distinct Signaling Nodes. Host cells were pre-infected with"/>
 <result pre="levels, and HSV-1 infection. Fig. 4 Drug Treatment of Viral" exact="Infection" post="Affecting Distinct Signaling Nodes. Host cells were pre-infected with"/>
 <result pre="but without virus. A. RIB reduced both pS6 level and" exact="viral" post="burden. B. pSTAT1 signaling was blocked in HSV-1 infected"/>
 <result pre="pMAPKAPK2 level was decreased by HSV-1 treatment, whereas blocking HSV-1" exact="infection" post="increased pMAPKAPK2 signaling. D. pNFĸB was induced in HSV-1"/>
 <result pre="from three independent experiments. 3.5 Monitoring cellular signaling and HSV-1" exact="infection" post="with simultaneous infection and treatment To confirm the correlations"/>
 <result pre="experiments. 3.5 Monitoring cellular signaling and HSV-1 infection with simultaneous" exact="infection" post="and treatment To confirm the correlations among RIB, pS6"/>
 <result pre="To confirm the correlations among RIB, pS6 signaling, and HSV-1" exact="infection" post="obtained in the initial screening, we investigated the state"/>
 <result pre="infected with HSV-1 (Fig. 5 A). In order to allow" exact="viral infection" post="to propagate adequately, we focused on the time point"/>
 <result pre="with HSV-1 (Fig. 5 A). In order to allow viral" exact="infection" post="to propagate adequately, we focused on the time point"/>
 <result pre="In this model, Optimal_A and Optimal_B both profoundly reduced HSV-1" exact="infections" post="compared to unstimulated controls (Fig. 5B). This result is"/>
 <result pre="findings (Ding et al., 2012). When we further compared HSV-1" exact="infection" post="levels (Fig. 5C) and pS6 levels (Fig. 5D), HSV-1"/>
 <result pre="infection levels (Fig. 5C) and pS6 levels (Fig. 5D), HSV-1" exact="infection" post="induced an increase in pS6 levels by 5–10 fold,"/>
 <result pre="fold, and RIB or the RIB-containing drug combination reduced percent" exact="infection" post="and pS6 levels following a similar pattern. Percent infection"/>
 <result pre="percent infection and pS6 levels following a similar pattern. Percent" exact="infection" post="plotted against pS6 levels revealed that viral infection followed"/>
 <result pre="similar pattern. Percent infection plotted against pS6 levels revealed that" exact="viral infection" post="followed a log-linear relationship with pS6 level (Fig. 5E)."/>
 <result pre="pattern. Percent infection plotted against pS6 levels revealed that viral" exact="infection" post="followed a log-linear relationship with pS6 level (Fig. 5E)."/>
 <result pre="combination to its antiviral effect. Fig. 5 Signaling In Simultaneous" exact="Infection" post="and Treatment. A. Host cells stimulated with drug combinations"/>
 <result pre="Treatment. A. Host cells stimulated with drug combinations and HSV-1" exact="infection" post="simultaneously for 16 h. B. Both drug combinations Optimal_A and"/>
 <result pre="B. Both drug combinations Optimal_A and Optimal_B profoundly reduced HSV-1" exact="infection" post="compared to unstimulated controls in the co-treated model. Data"/>
 <result pre="D. Drug treatments versus pS6 level showed similar patterns as" exact="viral infection." post="E. HSV-1 infection levels and S6 phosphorylation levels followed"/>
 <result pre="pS6 level showed similar patterns as viral infection. E. HSV-1" exact="infection" post="levels and S6 phosphorylation levels followed a log-linear correlation."/>
 <result pre="to validate the cause-effect relationships between pS6 signaling and HSV-1" exact="infection" post="using the pS6 kinase inhibitor, SL0101. To evaluate the"/>
 <result pre="down-regulating the S6 pathway on HSV-1 replication we looked at" exact="viral" post="replication 16 h after treatment with SL0101. At 50"/>
 <result pre="100 μM or RIB at 100 μM profoundly decrease the" exact="viral infection" post="level (Fig. 6 A). We also examined the effects"/>
 <result pre="μM or RIB at 100 μM profoundly decrease the viral" exact="infection" post="level (Fig. 6 A). We also examined the effects"/>
 <result pre="SL0101 both showed general signaling regulation across multiple pathways. With" exact="viral" post="stimulation, however, SL0101 at 25 and 50 μM no longer"/>
 <result pre="resulted in dramatic signaling regulation. This result shows that HSV-1" exact="infection" post="could overcome changes induced by low dose SL0101. However,"/>
 <result pre="such toxicity was not obvious based on observation of cellular" exact="morphology" post="in our in vitro study (Supplementary Fig. 5A) and"/>
 <result pre="present, SL0101 only down-regulated pS6 at 100 μM. Furthermore, with HSV" exact="infection" post="present, SL0101 did not obviously reduce viral infection levels"/>
 <result pre="Furthermore, with HSV infection present, SL0101 did not obviously reduce" exact="viral infection" post="levels at 50 μM, but infection levels were diminished at"/>
 <result pre="with HSV infection present, SL0101 did not obviously reduce viral" exact="infection" post="levels at 50 μM, but infection levels were diminished at"/>
 <result pre="did not obviously reduce viral infection levels at 50 μM, but" exact="infection" post="levels were diminished at 100 μM. Therefore, SL0101 regulates pS6"/>
 <result pre="dose-dependent manner in uninfected cells, but SL0101 treatment inhibits HSV" exact="infection" post="at a high dose in concordance with changes in"/>
 <result pre="a high dose in concordance with changes in pS6 during" exact="viral infection." post="3.7 Translating cellular signaling analysis: small molecule inhibition of"/>
 <result pre="3.7 Translating cellular signaling analysis: small molecule inhibition of HSV-1" exact="infection" post="in an animal model The ultimate goal of our"/>
 <result pre="this study we used a mouse model of vaginal HSV-1" exact="infection" post="as a way to assess the in vivo efficacy"/>
 <result pre="A depicts our setup of a model of HSV-1 vaginal" exact="infection" post="in mice. To ensure that the animal model could"/>
 <result pre="Optimal_B (RIB-rich treatments). Mice treated with ACV showed decreased HSV-1" exact="viral" post="load, especially on day 3. Remarkably, mice treated with"/>
 <result pre="with drug combination Optimal_B had HSV-1 levels that were 70-fold" exact="lower" post="than those of untreated mice on day 3 (Fig."/>
 <result pre="Treatment of HSV Infection. SL0101 (RSK p90 inhibitor) inhibited HSV-1" exact="infection" post="in vivo. A. Demonstration of the animal model used"/>
 <result pre="combination Optimal_B (high dose RIB and ACV) effectively prevented HSV-1" exact="infection" post="in the animal model, indicating that the animal model"/>
 <result pre="on the anti-HSV-1 potency of SL0101. C. SL0101 significantly reduced" exact="viral" post="burden in vivo. D. Unlike drug combination Optimal_B, which"/>
 <result pre="on day 2, SL0101 took longer (day 3) to induce" exact="viral" post="inhibition. Each experiment used nine animals for each data"/>
 <result pre="(Fig. 7A). Mice treated with SL0101 did not show significant" exact="viral" post="reduction compared to the untreated group on day 2."/>
 <result pre="2. However, the treated group showed more than 12 fold" exact="viral" post="reduction compared to untreated group on day 3 (Fig."/>
 <result pre="induced by any one drug, combination of drugs, or the" exact="disease" post="state can rapidly elucidate the intricate changes in cellular"/>
 <result pre="we present a study focusing on HSV-1 infection. While HSV-1" exact="infection" post="can be well controlled by currently available antivirals, we"/>
 <result pre="of anti-viral resistant strains, the possibility of HSV-1 inducing enhanced" exact="disease" post="in immunocompromised individuals, and the lack of an effective"/>
 <result pre="signatures when assayed by phosphoflow. Our results reveal that HSV-1" exact="infection" post="can be targeted using antivirals that modulate one of"/>
 <result pre="1996; Liu et al., 2012). This antiviral state efficiently blocks" exact="viral" post="growth and thus it makes sense as a marker"/>
 <result pre="The impact that modulation of S6 phosphorylation would have on" exact="viral" post="replication is not a well-understood idea. While HSV-1 replication"/>
 <result pre="theme of S6 manipulation by viruses is common in other" exact="viral" post="disease, S6 phosphorylation modulators may be a new class"/>
 <result pre="reducing HSV-1 replication in an animal model of vaginal HSV-1" exact="infection" post="shows how important it is to understand the changes"/>
 <result pre="the changes in cellular signaling that are effective in blocking" exact="viral infection." post="However, results of this study revealed that even without"/>
 <result pre="regulation of S6 phosphorylation occurs in cells with and without" exact="viral infection." post="Consequently, the consequences of changing the phosphorylation state of"/>
 <result pre="immense. We did not see any obvious changes in cellular" exact="morphology" post="nor changes in cell viability as assessed by MTT"/>
 <result pre="treatment. At one time, RIB was the major treatment for" exact="Hepatitis" post="C Virus infection but now RIB-independent therapies have become"/>
 <result pre="time, RIB was the major treatment for Hepatitis C Virus" exact="infection" post="but now RIB-independent therapies have become commonplace in the"/>
 <result pre="other viruses on the world stage, including MERS-CoV (Middle East" exact="Respiratory" post="Syndrome-Corona Virus), Lassa Fever Virus, and Zika virus (Kamiyama"/>
 <result pre="world stage, including MERS-CoV (Middle East Respiratory Syndrome-Corona Virus), Lassa" exact="Fever" post="Virus, and Zika virus (Kamiyama et al., 2017; Carrillo-Bustamante"/>
 <result pre="proof of principle in a mouse model of vaginal HSV-1" exact="infection" post="by targeting S6 phosphorylation directly with the S6 kinase"/>
 <result pre="and DJS designed experiments. References References Al-LazikaniB.BanerjiU.WorkmanP.Combinatorial drug therapy for" exact="cancer" post="in the post-genomic eraNat. Biotechnol.307201267969222781697 ArtsE.J.HazudaD.J.HIV-1 antiretroviral drug therapyCold"/>
 <result pre="Lassa virus infectionSci. Rep.7120171169328916737 ChongY.P.Antiviral treatment guidelines for Middle East" exact="respiratory" post="SyndromeInfect Chemother473201521222226483999 CoppinE.Flow cytometric analysis of intracellular phosphoproteins in"/>
 <result pre="evaluation of mek inhibitors as small-molecule therapeutics for B-cell precursor" exact="acute" post="lymphoblastic leukemiaPLoS One1092015e0137917 HildebrandD.KubatzkyK.F.Phospho-flow analysis of primary mouse cells"/>
 <result pre="for B-cell precursor acute lymphoblastic leukemiaPLoS One1092015e0137917 HildebrandD.KubatzkyK.F.Phospho-flow analysis of" exact="primary" post="mouse cells after HDAC inhibitor treatmentMethods Mol. Biol.1510201723324327761825 HorvathC.M.DarnellJ.E.Jr.The"/>
 <result pre="transcriptionally active Stat1 proteinJ. Virol.70119966476508523587 JamesS.H.PrichardM.N.Current and future therapies for" exact="herpes" post="simplex virus infections: mechanism of action and drug resistanceCurr"/>
 <result pre="of action and drug resistanceCurr Opin Virol82014546125036916 JohnstonC.CoreyL.Current concepts for" exact="genital herpes" post="simplex virus infection: diagnostics and pathogenesis of genital tract"/>
 <result pre="action and drug resistanceCurr Opin Virol82014546125036916 JohnstonC.CoreyL.Current concepts for genital" exact="herpes" post="simplex virus infection: diagnostics and pathogenesis of genital tract"/>
 <result pre="lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from" exact="neuronal" post="latencyScience3225899200826827118845757 KrutzikP.O.NolanG.P.Fluorescent cell barcoding in flow cytometry allows high-throughput"/>
 <result pre="LeeB.Y.Drug regimens identified and optimized by output-driven platform markedly reduce" exact="tuberculosis" post="treatment timeNat. Commun.820171418328117835 LiuS.Y.Systematic identification of type I and"/>
 <result pre="platform markedly reduce tuberculosis treatment timeNat. Commun.820171418328117835 LiuS.Y.Systematic identification of" exact="type I" post="and type II interferon-induced antiviral factorsProc. Natl. Acad. Sci."/>
 <result pre="tuberculosis treatment timeNat. Commun.820171418328117835 LiuS.Y.Systematic identification of type I and" exact="type II" post="interferon-induced antiviral factorsProc. Natl. Acad. Sci. U. S. A.1091120124239424422371602"/>
 <result pre="of drug combinations using feedback system controlNat. Protoc.112201630231526766116 PiretJ.BoivinG.Resistance of" exact="herpes" post="simplex viruses to nucleoside analogues: mechanisms, prevalence, and managementAntimicrob."/>
 <result pre="SauerbreiA.Optimal management of genital herpes: current perspectivesInfect. Drug Resist.9201612914127358569 SchweizerL.ZhangL.Enhancing" exact="cancer" post="drug discovery through novel cell signaling pathway panel strategyCancer"/>
 <result pre="Metastasis62013535924665207 SilvaA.Output-driven feedback system control platform optimizes combinatorial therapy of" exact="tuberculosis" post="using a macrophage cell culture modelProc. Natl. Acad. Sci."/>
 <result pre="Med.52052013205rv1 TeH.S.RandallG.JensenD.M.Mechanism of action of ribavirin in the treatment of" exact="chronic hepatitis" post="CGastroenterol Hepatol (N Y)33200721822521960835 TognarelliE.I.Herpes simplex virus evasion of"/>
 <result pre="TeH.S.RandallG.JensenD.M.Mechanism of action of ribavirin in the treatment of chronic" exact="hepatitis" post="CGastroenterol Hepatol (N Y)33200721822521960835 TognarelliE.I.Herpes simplex virus evasion of"/>
 <result pre="for 48 h. After which they were observed for changes in" exact="morphology" post="that would be a sign of SL0101 induced cytotoxicity."/>
</results>
